Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...

After re-examining its initial opinion, EMA’s human medicines committee, or CHMP, has recommended granting a marketing authorisation to Leqembi for treating mild cognitive impairment or mild dementia ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...

The team determined genetic risk using polygenic risk scores for stroke and depression, and utilized Apolipoprotein E (APOE) ...

Consolidated revenue of €3.4m at the end of September 2024 Cash position of €4.1m before receipt of IRIS Pharma's CIR (€610k) as of September 30, 2024 Live broadcast of the General Meeting ...

The European Medicines Agency (EMA) has given the green light for the first Alzheimer's therapy in the EU that targets the ...

COG 133作为一种多功能的肽片段，在调节脂质代谢、抗炎、神经保护以及影响神经递质受体功能等方面展现出潜在的治疗价值。其作为nAChR拮抗剂的特性也为神经系统疾病的治疗提供了新的思路和靶点。未来，COG ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

A study led by a team of scientists in Ghana and Nigeria has revealed that nearly a third of Ghanaians-29.7% carry two copies of the Apolipoprotein LI (APOL1) gene variants increasing their risk of ...

The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.